Details for New Drug Application (NDA): 219474
✉ Email this page to a colleague
The generic ingredient in ADQUEY is difamilast. One supplier is listed for this compound. Additional details are available on the difamilast profile page.
Summary for 219474
| Tradename: | ADQUEY |
| Applicant: | Acrotech Biopharma |
| Ingredient: | difamilast |
| Patents: | 2 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 219474
Generic Entry Date for 219474*:
Constraining patent/regulatory exclusivity:
Dosage:
OINTMENT;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 219474
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ADQUEY | difamilast | OINTMENT;TOPICAL | 219474 | NDA | Acrotech Biopharma Inc | 72893-017 | 72893-017-07 | 3 g in 1 TUBE (72893-017-07) |
| ADQUEY | difamilast | OINTMENT;TOPICAL | 219474 | NDA | Acrotech Biopharma Inc | 72893-017 | 72893-017-08 | 27 g in 1 TUBE (72893-017-08) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | OINTMENT;TOPICAL | Strength | 1% | ||||
| Approval Date: | Feb 12, 2026 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Feb 12, 2031 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | 10,588,893 | Patent Expiration: | Dec 31, 2036 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | RE46792 | Patent Expiration: | Mar 1, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | METHOD OF TREATING ATOPIC DERMATITIS | ||||||||
Complete Access Available with Subscription
